Bibliographie (2530)
Antibody responses after a single dose of AstraZeneca Covid-19 vaccine in previously infected individuals were similar or higher compared to SARS-CoV-2 naïve participants who received two doses of Pfizer mRNA vaccine.
lundi, 16 août 2021 03:23 Écrit par Zouhair SouissiAntibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2 – EBioMedicine Commentary (on the preprint): Single dose of Oxford-AstraZeneca vaccine protective in previously infected recipients, suggests study – News Medical Related: More data showing one dose of Pfizer vaccine may be enough for individuals who’ve had COVID. […]
The post Antibody responses after a single dose of AstraZeneca Covid-19 vaccine in previously infected individuals were similar or higher compared to SARS-CoV-2 naïve participants who received two doses of Pfizer mRNA vaccine. appeared first on Links Medicus.
Perspective | Don’t panic, but breakthrough cases may be a bigger problem than you’ve been told.
lundi, 16 août 2021 03:23 Écrit par Zouhair SouissiDon’t Panic, But Breakthrough Cases May Be a Bigger Problem Than You’ve Been Told – Intelligencer Commentary on Twitter (thread – click for more) The vaccines are still performing quite well in preventing severe disease. But with Delta they are doing much worse in stopping transmission. Breakthroughs are probably now 10-20% of new infections, […]
The post Perspective | Don’t panic, but breakthrough cases may be a bigger problem than you’ve been told. appeared first on Links Medicus.
FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now.
lundi, 16 août 2021 03:23 Écrit par Zouhair SouissiCoronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals – U.S. Food & Drug Administration Commentaries: Statement on FDA Authorization of Supplemental Vaccine Dose for Immunocompromised Patients – Infectious Diseases Society of America CDC, FDA recommend COVID booster for immune-compromised – CIDRAP FDA authorizes additional dose of Covid-19 vaccine for the immunocompromised […]
The post FDA authorizes additional Covid-19 vaccine dose for certain immunocompromised individuals – Other fully vaccinated individuals do not need an additional vaccine dose right now. appeared first on Links Medicus.
Opinion: Time for a smart approach to boosters.
vendredi, 13 août 2021 12:16 Écrit par Zouhair SouissiTime for a Smart Approach to Boosters – Think Global Health
The post Opinion: Time for a smart approach to boosters. appeared first on Links Medicus.
How do vaccinated people spread Delta? What the science says.
vendredi, 13 août 2021 12:16 Écrit par Zouhair SouissiHow do vaccinated people spread Delta? What the science says – Nature
The post How do vaccinated people spread Delta? What the science says. appeared first on Links Medicus.
How COVID-19 will change the management of other respiratory viral infections.
vendredi, 13 août 2021 12:16 Écrit par Zouhair SouissiHow COVID-19 will change the management of other respiratory viral infections – Intensive Care Medicine Commentary on Twitter Still in the midst of #SARSCoV2 #pandemic, still so much to learn… but #COVID19 experience should transform approach to research on RVIs?antiviral therapy?corticosteroids?specific immune modulation?anticoagulation?respiratory support#COVIDFOAM https://t.co/WVKRSJARvl pic.twitter.com/qMkB4tkz06 — Intens Care Med (@yourICM) August 11, 2021 […]
The post How COVID-19 will change the management of other respiratory viral infections. appeared first on Links Medicus.
Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.
vendredi, 13 août 2021 12:16 Écrit par Zouhair SouissiKawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison – American Family Physician Related: Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children. Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) […]
The post Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison. appeared first on Links Medicus.
Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).
vendredi, 13 août 2021 12:16 Écrit par Zouhair SouissiCould This Be Our First Effective, Inexpensive, Widely Available Outpatient Treatment for COVID-19? – HIV and ID Observations Related: Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19
The post Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine). appeared first on Links Medicus.
M-A of randomized trials: proton pump inhibitors for gastro-esophageal reflux disease does not improve outcomes in patients with asthma.
vendredi, 13 août 2021 11:14 Écrit par Zouhair SouissiRandomised trials of proton pump inhibitors for gastro-oesophageal reflux disease in patients with asthma: an updated systematic review and meta-analysis – BMJ Open
The post M-A of randomized trials: proton pump inhibitors for gastro-esophageal reflux disease does not improve outcomes in patients with asthma. appeared first on Links Medicus.
Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time.
jeudi, 12 août 2021 14:27 Écrit par Zouhair SouissiModerna may be superior to Pfizer against delta variant — breakthrough odds rise with time – CNBC Original Study 1 (preprint): Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence – medRxiv Original Study 2 (preprint): Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home […]
The post Moderna may be superior to Pfizer against Delta variant — breakthrough odds rise with time. appeared first on Links Medicus.
![[Preprint] Pfizer vs. Moderna COVID-19 vaccine effectiveness against the Delta variant in Qatar – Effectiveness against symptomatic disease due to Delta was 53.5% for Pfizer and 84.8% for Moderna; effectiveness against severe disease due to Delta was 89.7](/media/k2/items/cache/2be14c7bf5e582e3d07cf6fdbe198e16_XS.jpg)
